Navigation Links
Ibrutinib Phase 2 Data: Analyses Show Efficacy with Ibrutinib Monotherapy in Patients with Relapsed or Refractory Mantle Cell or Diffuse Large B-cell Lymphoma
Date:6/16/2013

the ABC subtype, compared to 3.35 months for the GCB subtype (p=0.05).
  • Within the ABC subtype group, only patients who had a CD79B mutation responded to treatment; patients with only an MYD88 mutation did not respond to treatment, suggesting a MYD88-dependent but BCR-independent pathogenesis for some DLBCL tumors.
  • Safety data from 70 patients identified no new safety signals. Grade 3 or higher AEs were seen in greater than 3% of patients and included fatigue (9%), hyponatremia (9%), pneumonia (7%), dehydration (4%), and pleural effusion (4%).
  • "These results indicate the important function BTK plays in the survival of ABC type DLBCL," explained presenting investigator Sven de Vos, M.D., Ph.D., Associate Professor in the Department of Medicine at the UCLA Medical Center, Los Angeles, who reported the results at the EHA Congress today. "Seeing clinically meaningful responses among the ABC subtype was encouraging, as patients at this stage are challenging to treat. Additional trials among this patient group are ongoing."

    The DLBCL study was a Phase 2 multicenter, open-label, study that included 70 patients with relapsed/refractory DLBCL with a median of three prior therapies. All patients underwent gene expression profiling to determine their DLBCL subtype, 29 patients were identified with the ABC subtype, and 20 with the GCB subtype. Patients received ibrutinib 560 mg orally, once a day, until disease progression or unacceptable toxicity. The primary objective of the study was to assess ORR categorized by subtype, with secondary objectives being to assess the safety and tolerability of ibrutinib in people with DLBCL.

    About Ibrutinib
    Ibrutinib is an investigational, oral BTK inhibitor. The effectiveness and safety of ibrutinib alone or in combination with other treatments is being studied in several B-cell malignancies.

    Janssen Biotech, Inc. and Pharmac
    '/>"/>

    SOURCE Janssen
    Copyright©2012 PR Newswire.
    All rights reserved

    Page: 1 2 3 4 5 6

    Related medicine technology :

    1. Pharmacyclics Announces Oral Presentations and Clinical Update of Ibrutinib (PCI-32765) at the 2012 Annual Meeting of the American Society of Clinical Oncology
    2. Pharmacyclics Announces Oral Presentations of Ibrutinib (PCI-32765) at the 17th Congress of the European Hematology Association
    3. Follow-up Results of Phase 2 Study of Investigational Agent, Ibrutinib, Suggest High and Durable Responses in Relapsed/Refractory Mantle Cell Lymphoma
    4. Follow-up Results of Phase 2 Study of Investigational Agent, Ibrutinib, in Relapsed/Refractory Mantle Cell Lymphoma Presented at American Society of Hematology Annual Meeting
    5. Ibrutinib Receives Two Oncology Breakthrough Therapy Designations from U.S. Food and Drug Administration
    6. Pharmacyclics Announces Third Breakthrough Therapy Designation for Ibrutinib from the U.S. Food and Drug Administration
    7. Phase II Ibrutinib Monotherapy Study Shows CLL Patients Achieved Rapid and Sustainable Disease Control Irrespective of Age or High Risk Prognostic Factor
    8. Ibrutinib Expanded Access Program Open to Eligible U.S. Patients with Relapsed or Refractory Mantle Cell Lymphoma
    9. Argos Therapeutics Secures $25 million Series D Financing to Commence Phase 3 ADAPT Study in Patients with Metastatic Renal Cell Carcinoma (mRCC) in Mid-2012
    10. Anthera Announces the Completion of Patient Dosing in Phase 2b PEARL-SC Study
    11. Omthera Pharmaceuticals Announces Positive Top-Line Results from Phase 3 EVOLVE Study
    Post Your Comments:
    *Name:
    *Comment:
    *Email:
    (Date:1/15/2014)... 2014  A novel wearable injector slightly larger than an Oreo ... to self-inject prescription drugs in the large doses required to ... autoimmune deficiencies, and genetic disorders.  An emerging ... 2018, according to analysts.   Many of these drugs will require ...
    (Date:1/14/2014)... N.J. , Jan. 14, 2014 InformEx, ... and sellers of high-value chemistry, will hold the 30 th ... Miami Beach Convention Center from January 21-24. ... 3,500 attendees from top pharmaceutical, fine chemical and specialty chemical ...
    (Date:1/14/2014)... 2014 /PRNewswire-iReach/ -- Acumed,s new SLIC Screw System - ... instrumentation to place and insert the screw accurately - ... (e.g. ligament) repair or reconstruction as it holds the ... (Photo: http://photos.prnewswire.com/prnh/20140114/MN45636 ) The SLIC ...
    Breaking Medicine Technology:Enable Injections Presents A New Class of Injectors for Drug Delivery at PEPTalk, Drug Delivery Partnership Meetings 2Media Advisory: InformEx 2014 Events & Speaker Lineup for 30th Edition Conference in Miami Beach 2Acumed introduces the Scapho-Lunate Inter Carpal (SLIC) Screw System 2Acumed introduces the Scapho-Lunate Inter Carpal (SLIC) Screw System 3
    (Date:7/9/2014)... of stromal support cells and immune cells and ... in the development of diseases could open new ... was the conclusion of a review article by scientists ... Nature . , Prof. Peter Carmeliet: "Consider the ... of cancer cells has been examined in minute detail ...
    (Date:7/9/2014)... BostonPractices used in policing injection drug users in ... mortality. , A study, conducted by researchers ... Health, in collaboration with St. Petersburg Pavlov State ... had on the health outcomes of a cohort ... use. , Those who were arrested by police ...
    (Date:7/9/2014)... French . By ... including brain structure and function, personality, life experiences and genetics, ... to develop binge drinking within the next two years. Impulsivity, ... as life events and a family history of drug use ... not the child had had a single drink at age ...
    (Date:7/9/2014)... extinctions around the world have been linked to ... research from the National Institute for Mathematical and ... may also contribute. , In a series ... causes severe hemorrhage of internal organs in frogs, ... frogs if they are exposed to the virus ...
    (Date:7/9/2014)... and Infectious Diseases (NIAID), part of the National ... trial of CRS3123, an investigational oral antibiotic intended ... difficile ) infection. CRS3123 (previously known as REP3123) ... growth while sparing normal intestinal bacteria. , The ... healthy men and women ages 18 to 45 ...
    Breaking Medicine News(10 mins):Health News:Wake-up call for more research into cell metabolism 2Health News:BU researchers relate arrests with HIV risk environment 2Health News:What drives a child to abuse alcohol? 2Health News:Study predicts ranavirus as potential new culprit in amphibian extinctions 2Health News:NIH launches Phase I clinical trial of novel drug to treat Clostridium difficile infection 2
    ... Food Safety in Sunshine State by Using ... Food-Borne Illness, LANSING, Ill., Feb. 7 National ... Egg restaurants in,Lakewood Ranch and Sarasota, Fla., will now ... for all dishes requiring eggs., By using Davidson,s ...
    ... Lotus Pharmaceuticals,Inc. (OTC Bulletin Board: LTUS) ("Lotus" ... People,s Republic of China ("PRC"), today,announced that ... owned,subsidiary of Lotus, has implemented cost saving ... costs by approximately 50%., The environmentally-friendly ...
    ... hours and more than 300 people in the UK die ... with permanent disabilities. Now researchers will work on a potential ... the medical charity Meningitis UK. , Although vaccines exist to ... vaccine to protect against all strains, including the most common ...
    ... E. Borlaug Hall of Laureates, DES MOINES, Iowa, ... a $1 million contingent donation to fund the establishment,of ... Des Moines. The donation,will support the transformation of the ... Hall of Laureates and will be administered,through DuPont business ...
    ... New Fresh Plum Juice Boasts Digestive Health Benefits with 60 Percent Less ... ... Due to the overwhelming,success of PlumSmart plum juice, Sunsweet Growers Inc. has ... three grams of fiber in each glass and only 11 grams of,sugar, ...
    ... All Existing Markets -, LONG BEACH, N.Y., Feb. ... PMQCW), the third largest long-term care,pharmacy, today announced that ... across all four of its institutional pharmacies,which serve a ... City,metropolitan area, as well as parts of New Jersey, ...
    Cached Medicine News:Health News:Popular Florida Restaurant Leads Hospitality Industry by Converting to Pasteurized Shell Eggs Usage 2Health News:Lotus Pharmaceuticals, Inc. Implements Environmentally-friendly Cost Saving Strategies 2Health News:Meningitis vaccine study gets £200,000 boost 2Health News:DuPont Pledges $1 Million to World Food Prize 2Health News:DuPont Pledges $1 Million to World Food Prize 3Health News:Sunsweet Introduces PlumSmart Light(R) 2Health News:Chem Rx Surpasses 65,000 Residents Served 2
    Subretinal Fluid Cannula, Curved; 20g (0.90) x 1-1/2" (38mm); 12mm Flexible Tubing Extends 6mm Beyond Tip; Curved at 65°....
    Injection Cannula, Straight; 20g (0.90) x 1" (25mm); Tip Extension: 5mm, 30g (0.30)....
    ...
    PremierEdge™ Slit Knives....
    Medicine Products: